Bonatti Rodolfo, Silva Ana Flavia Garcia, Batatinha Julio Americo Pereira, Sobrado Lucas F, Machado Ananda Dianni, Varone Bruno B, Nearing Bruce D, Belardinelli Luiz, Verrier Richard L
Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Heart Rhythm. 2014 Oct;11(10):1827-35. doi: 10.1016/j.hrthm.2014.06.017. Epub 2014 Jun 17.
Ischemic heart disease is associated with dual risk for atrial and ventricular arrhythmias.
We examined whether selectively targeting late sodium channel current (INa) with GS-458967 (hereafter GS967) can reduce cardiac electrical instability and compared its effects to a clinically relevant dose of flecainide.
Electrode catheters were positioned on the left atrial appendage and left ventricle of anesthetized pigs to monitor repolarization alternans and electrocardiographic heterogeneity before and during left circumflex coronary artery stenosis (75% flow reduction) before and after GS967 (0.4 mg/kg, intravenously [IV]) or flecainide (1 mg/kg, IV, bolus over 2 minutes followed by 1 mg/(kg·h), IV, for 1 hour) administration.
Left circumflex coronary artery stenosis increased atrial repolarization alternans by 520% (from 9.4 ± 1.2 to 58.3 ± 11.3 μV; P = .029) and T-wave alternans by 1038% (from 30.7 ± 8.2 to 349.3 ± 103.8 μV; P = .049). GS967 prevented ischemia-induced increases in alternans in the left atrium (19.3 ± 5.6 μV vs 58.3 ± 11.3 μV; P = .023) and left ventricle (217.9 ± 95.8 μV vs 349.3 ± 103.8 μV; P < .001) (n = 7). GS967 reduced ischemia-induced increases in depolarization heterogeneity (atrium: from 45% to 28%; ventricle: from 92% to 51%) and repolarization heterogeneity (atrium: 43% to 23%; ventricle: 137% to 91%). GS967 did not alter heart rate, arterial blood pressure, PR and QT intervals, or QRS duration, but it mildly decreased contractility (left ventricular dP/dt) during ischemia, which was consistent with late INa inhibition. Flecainide (n = 7) amplified ischemia-induced increase in atrial and ventricular repolarization alternans, electrocardiographic heterogeneity, and ventricular fibrillation incidence.
Selective late INa inhibition with GS967 exerts potent protective effects against ischemia-induced depolarization and repolarization abnormalities in both atria and ventricles.
缺血性心脏病与心房和心室心律失常的双重风险相关。
我们研究了用GS - 458967(以下简称GS967)选择性靶向晚钠电流(INa)是否能降低心脏电不稳定性,并将其效果与临床相关剂量的氟卡尼进行比较。
将电极导管置于麻醉猪的左心耳和左心室,以监测左旋冠状动脉狭窄(血流减少75%)前后、GS967(0.4mg/kg,静脉注射[IV])或氟卡尼(1mg/kg,IV,2分钟内推注,随后1mg/(kg·h),IV,持续1小时)给药前后的复极交替和心电图异质性。
左旋冠状动脉狭窄使心房复极交替增加520%(从9.4±1.2μV增至58.3±11.3μV;P = 0.029),T波交替增加1038%(从30.7±8.2μV增至349.3±103.8μV;P = 0.049)。GS967可预防缺血引起的左心房(19.3±5.6μV对58.3±11.3μV;P = 0.023)和左心室(217.9±95.8μV对349.3±103.8μV;P < 0.001)复极交替增加(n = 7)。GS967可降低缺血引起的去极化异质性增加(心房:从45%降至28%;心室:从92%降至51%)和复极异质性增加(心房:从43%降至23%;心室:从137%降至91%)。GS967未改变心率、动脉血压、PR和QT间期或QRS时限,但在缺血期间轻度降低了收缩性(左心室dP/dt),这与晚INa抑制一致。氟卡尼(n = 7)放大了缺血引起的心房和心室复极交替增加、心电图异质性增加以及心室颤动发生率。
用GS967选择性抑制晚INa对缺血引起的心房和心室去极化及复极异常具有强大的保护作用。